← Back to all trials
Completed
NCT03691714
Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Conditions: Recurrent Head and Neck Cancer, Head and Neck Cancer, Head and Neck Neoplasms, Metastatic Cancer
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE2
Enrollment: 35
Sponsor: Trisha Wise-Draper
Location: UC Health Cincinnati Ohio
Summary
The purpose of this research study is to test the combination of the anti-cancer drugs durvalumab, the study drug, and cetuximab as a treatment for metastatic or recurrent head and neck cancer. Participants will receive both durvalumab and cetuximab.
Eligibility Criteria
Inclusion Criteria:
* Body weight \> 30 kg
* Histologically or cytologically confirmed recurrent or metastatic HNSCC
* Not considered a candidate for other curative therapy (i.e. surgery/RT)
* Documented progression of disease after receiving platinum based regimen
* ECOG performance status 0-2
Exclusion Criteria:
* Nasopharyngeal and salivary gland tumors
* Prior exposure to both immunotherapy drugs and Cetuximab. Single exposure to either immunotherapy or cetuximab is allowed.
Source: ClinicalTrials.gov (NCT03691714). StuddyBuddy aggregates publicly available trial information.
